Figure 10

Soluble c-kit in serum levels in patients with asthma, aspirin hypersensitivity and nasal polyps (ASA group, n = 11) and in patients with asthma without aspirin hypersensitivity and nasal polyps (ATA group, n = 20) (* p < 0,05).